Reeling from Covid flop, Icosavax says its RSV candidate passed early test. But investors need some more convincing

Amber Tong

Three months separated from a disappointing readout of its Covid-19 vaccine, Icosavax is back with what it calls positive topline data for a different VLP …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Reeling from Covid flop, Icosavax says its RSV candidate passed early test. But investors need some more convincing

Amber Tong

Sign up to read this article for free.

Pfizer looking to sell hospital drugs unit — reports

'Expertise is a real thing': FDA commissioner warns of political risk to agency

AstraZeneca CEO reaffirms commitment to China following executive's detention

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Reel­ing from Covid flop, Icosavax says its RSV can­di­date passed ear­ly test. But in­vestors need some more con­vinc­ing

Amber Tong

Sign up to read this article for free.

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Reeling from Covid flop, Icosavax says its RSV candidate passed early test. But investors need some more convincing

Pfizer looking to sell hospital drugs unit — reports

'Expertise is a real thing': FDA commissioner warns of political risk to agency

AstraZeneca CEO reaffirms commitment to China following executive's detention

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?